SLNO - NASDAQ
Soleno Therapeutics, Inc.
$53.01
+0.038%Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
At a Glance
Live SnapshotSoleno Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Soleno Therapeutics, Inc. Income Statement
SLNO • NASDAQ
| Soleno Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
190.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.6B | 1.5M | 387.6K | 0.0 | 3M | 0.0 | |
GROSS PROFIT | ||||||||||||||
(2.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (2.2M) | (2.3M) | (1.9M) | (1.6M) | (1.5M) | (352.7K) | (0.0) | (0.0) | (0.0) | |
187.7M | 0.0 | 0.0 | 0.0 | 0.0 | -2.2M | -2.3M | -1.9M | -1.6B | -58.5K | 34.9K | 0.0 | 3M | 0.0 | |
OPERATING INCOME | ||||||||||||||
(172.8M) | (187.7M) | (41.4M) | (24.4M) | (31.5M) | (29.8M) | (20.9M) | (13.7M) | (9.7M) | (13.6M) | (12.2M) | (5.2M) | (3.8M) | (3.6M) | |
(132.1M) | (105.9M) | (13.5M) | (9.8M) | (10.8M) | (6.6M) | (4.6M) | (6.6M) | (6.6M) | (8.4M) | (7.9M) | (2.9M) | (1.5M) | (1.1M) | |
(40.6M) | (78.6M) | (25.2M) | (15.3M) | (21.5M) | (23.2M) | (16.3M) | (7.2M) | (3.1M) | (5.2M) | (4.5M) | (2.2M) | (2.4M) | (2.5M) | |
15M | -187.7M | -41.4M | -24.4M | -31.5M | -31.9M | -23.2M | -14.3M | -12.2M | -13.6M | -12.2M | -5.2M | -846.8K | -3.6M | |
PRE-TAX INCOME | ||||||||||||||
(5.5M) | (231K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (62K) | (0.0) | (0.0) | (3M) | (4.1M) | (2.9M) | (2.9M) | |
11.5M | 11.8M | 2.6M | 300K | 110K | 13K | 154K | 0.0 | 0.0 | 0.0 | -3M | -4.1M | -2.9M | -2.9M | |
(0.0) | (3.2M) | (2.7M) | -712K | -731K | (0.0) | (0.0) | (6K) | -585.9K | -100.5K | -183.6K | (0.0) | -2K | -22.4K | |
5.9M | 11.8M | 2.4M | 330K | 618K | 7.3M | -7.6M | 2.5M | -1.3M | 1.6M | -3.7M | -8.1M | -2.9M | -2.9M | |
20.9M | -175.9M | -39M | -24.1M | -30.9M | -24.6M | -30.8M | -11.8M | -13.7M | -12M | -15.9M | -13.9M | -3.7M | -6.5M | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1.7M | (21.7K) | (0.0) | -455.1K | (0.0) | (0.0) | |
20.9M | -175.9M | -39M | -24.1M | -30.9M | -24.6M | -30.8M | -13.3M | -15.7M | -12.1M | -15.9M | -13.9M | -3.7M | -6.5M |
SEC Filings
SLNO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 23, 2026 | January 21, 2026 | 2026 |
Related Guides
Continue your SLNO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.